Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biogipuzkoa (10)

2024

  1. AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

    Science advances, Vol. 10, Núm. 41, pp. eadn6525

  2. Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

    Journal of Medicinal Chemistry, Vol. 67, Núm. 18, pp. 16533-16555

  3. Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis

    Acta Neuropathologica, Vol. 148, Núm. 1

2023

  1. The rates of adult neurogenesis and oligodendrogenesis are linked to cell cycle regulation through p27-dependent gene repression of SOX2

    Cellular and Molecular Life Sciences, Vol. 80, Núm. 1

2021

  1. Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy

    Molecular Therapy - Nucleic Acids, Vol. 26, pp. 174-191

2019

  1. Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 50, pp. 25203-25213

2016

  1. Identification and Characterization of the Dermal Panniculus Carnosus Muscle Stem Cells

    Stem Cell Reports, Vol. 7, Núm. 3, pp. 411-424

  2. Six serum miRNAs fail to validate as myotonic dystrophy type 1 biomarkers

    PLoS ONE, Vol. 11, Núm. 2

2013

  1. Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients

    Human Molecular Genetics, Vol. 22, Núm. 4, pp. 704-716

  2. Production of human tissue-engineered skin trilayer on a plasma-based hypodermis

    Journal of Tissue Engineering and Regenerative Medicine, Vol. 7, Núm. 6, pp. 479-490